Lördag 21 December | 15:47:44 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2026-02-26 07:00 Bokslutskommuniké 2025
2025-11-20 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-20 07:00 Kvartalsrapport 2025-Q1
2025-04-15 N/A Årsstämma
2025-02-27 07:00 Bokslutskommuniké 2024
2024-11-18 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2024-04-16 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-04-13 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2023-04-12 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-24 - Kvartalsrapport 2022-Q1
2022-04-13 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2022-04-12 - Årsstämma
2022-02-22 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-11-17 - Extra Bolagsstämma 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-27 - Kvartalsrapport 2021-Q1
2021-04-07 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2021-04-06 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-09-01 - Extra Bolagsstämma 2020
2020-08-28 - Kvartalsrapport 2020-Q2

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nanoform Finland är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av tekniska produkter som används för att skapa nanopartiklar i läkemedel. Tekniken används som komplement i produktionsprocessen och används för behandling av sjukdomar som ALS och Alzheimers. Kunderna består av aktörer inom den globala läkemedelsindustrin. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingfors.
2024-02-16 10:00:00

Press release

Nanoform Finland Plc

February 16, 2024

11:00 a.m. Finnish time / 10:00 a.m. Swedish time

Invitation to Nanoform's Q4 and FY 2023 Report Presentation

Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, will publish its Q4 and FY 2023 report on February 29, 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.

The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO Christian Jones. The presentation will be delivered in English.

The presentation will be broadcast live as a webcast available at:

https://ir.financialhearings.com/nanoform-q4-report-2023

Teleconference dial-in numbers:

Dial-in number to the teleconference will be received by registering via the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. Questions can be presented by this dial-in function.

https://conference.financialhearings.com/teleconference/?id=50046525

For further information, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.